Abstract
Purpose :
To evaluate the clinical efficacy of continuous subtenon administration in the treatment of experimental staphylococcal endophthalmitis.
Methods :
Rabbits (n=40) were randomly divided into subtenon continuous administration group (n=20) and intravenous administration group (n=20). Animal models of bacterial endophthalmitis were established in all rabbits by intravitreal injection of 100 U Staphylococcus aureus. Continuous subtenon administration was initiated by injecting 0.3 ml norvancomycin into the subTenon in rabbits through a modified automatic infusion pump, and then continued daily treatment of norvancomycin at a rate of 0.1 ml/h.In the intravenous administration group, 1 mg norvancomycin was supplemented by 20 mg norvancomycin intravenously every day.The changes of cornea, iris, anterior chamber, vitreous body and retina were observed by slit lamp microscopy every day. According to the severity of inflammation, the inflammation scores were evaluated to 0, 1, 2, 3 and 4 respectively.
Results :
The inflammation score of the continuous subtenon group was significantly lower than that of intravenous group during the treatment period. On the third day after inoculation, the peak value of inflammation development appeared in continuous subtenon group (19.8 ±4.13). After treatment, the inflammation gradually relieved and the inflammation score decreased.In intravenous administration group, the peak inflammation appeared on the 3rd day after inoculation (24.3 ± 4.08), and decreased slightly on the 6th day after inoculation (23.1 ± 6.84). On the 7th day after inoculation, it rose again to 23.5±6.11. The inflammation score of the continuous subtenon group was significantly different from that of the intravenous administration group (P=0.019, LSD test).
Conclusions :
Continuous subtenon administration can significantly inhibit the inflammatory response of bacterial endophthalmitis compared with intravenous administration. It is an effective adjuvant therapy for infective endophthalmitis.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.